Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3

Fig. 1

Study design and side effects of CPA-7 for in vivo treatment evaluated by body weight. a, schematic illustration of the study design. CPA-7 was administrated by tail vein injection at three different doses. Injection of PBS containing 1 % DMSO (vehicle) served as control. An additional three groups of animals were used to evaluate tumor recurrence. These mice were subjected to surgical ablation two days post CPA-7 treatment and followed up for total of 60 days. b, effects of CPA-7 treatment on body weight in RM-9 tumor bearing mice. n = 9 ~ 11 for each group. c, effects of CPA-7 treatment on body weight in tumor bearing mice after surgery. n = 10 ~ 12 for each group. d, effects of CPA-7 treatment on body weight in healthy mice. n = 10 for each group. *, P < 0.05, **, P < 0.01, ***, P < 0.001 when compared with vehicle group

Back to article page